Reuters logo
BRIEF-Sangamo says patient received therapy intended to precisely edit DNA of cells directly inside body​
November 15, 2017 / 6:27 AM / a month ago

BRIEF-Sangamo says patient received therapy intended to precisely edit DNA of cells directly inside body​

Nov 15 (Reuters) - Sangamo Therapeutics Inc -

* Sangamo announces treatment of first patient in landmark phase 1/2 clinical trial evaluating in vivo genome editing for MPS II

* ‍A patient has received a therapy intended to precisely edit DNA of cells directly inside body​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below